Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...